In the Philippines, an estimated 7.3 million adults live with chronic hepatitis B, far above regional averages. Experts warn that complex treatment guidelines may hinder front-line clinicians from initiating care, while Thailand’s success with vaccination shows a path to elimination. Expanding screening and simplifying treatment are critical steps.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07128550 |
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
ACTIVE_NOT_RECRUITING | PHASE3 |
